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Methods

74
Study design and cases
75
The CANDIPOP project (ClinicalTrials.gov registry NCT01236261) is a 76 prospective, population-based surveillance cohort study on BSI due to Candida, 77 carried out between May 2010 and April 2011 in 29 Spanish hospitals. The 78 design and inclusion criteria have been described previously [6] [7] [8] [9] . In summary, M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
7 included if they received at least 24 hours of therapy); and (c) the isolate was 109 susceptible to both fluconazole and at least one of the echinocandins according 110 to EUCAST criteria [12] , so that only cases with both availble options were 111 considered. All cases due to C. krusei and cases due to C. glabrata resistant to 112 fluconazole were therefore excluded from the TTC. The analyses were 113 performed on both cohorts on an intention-to-treat basis for the first targeted 114 antifungal used as empirical or targeted therapy. Two investigators (LELC and 115 JRB) independently assessed inclusion to cohorts and therapy groups.
116
The local institutional review boards approved the study and written 117 consent was obtained from the patients. This analysis was reported following 118 the STROBE recommendations [13] . 
Variables and definitions
121
Clinical data were assessed at baseline, daily during therapy, at the end 122 of intravenous and oral therapy, and at weeks 2 and 6 after the end of all 123 antifungal therapy. Mortality was assessed at day 30 after the BSI.
124
The main outcome variable was all-cause mortality until day 30. 
131
The following data were recorded: age, gender; type of hospital service; 132 previous or present ICU admission; antifungals use in the previous month; use M A N U S C R I P T A C C E P T E D 
Microbiological data
158
The microbiological methods have been described previously [6] [7] [8] [9] 
Results
208
The CANDIPOP cohort included 752 cases of candidemia in 729 209 patients; 316 cases were included in the ETC and 421 in the TTC (Figure 1 ). Table 3 ).
234
The multivariate Cox regression model for ETC cohort is shown in Table   235 2. Interactions between empirical therapy with fluconazole and severe sepsis or 236 septic shock, unknown source, and C. albicans were studied and ruled out.
237
Empirical treatment with fluconazole was associated with better prognosis 238 (Table 2 ; HR 0.38; 95% CI, 0.17-0.81; p 0.01).
239
The multivariate Cox regression model for TTC cohort is shown in Table   240 2. Interactions between targeted therapy and early catheter removal, severe 241 sepsis or septic shock, and unknown source were tested and ruled out. There 
258
We also performed a sensitivity analysis for cases with severe sepsis or found that echinocandins were associated with a lower adjusted all-cause 30-295 day mortality and success rate [23] . However, the results of this study were 296 criticised because the heterogeneity of studies was not considered (it was not a 297 meta-analysis), and the fact that echinocandins were investigated in the more 298 recent studies but the impact of changes in care over the years was not 299 controlled in the analysis [24] . Finally, an observational study carried out in one M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
15 associated with a better prognosis than fluconazole [25] . However, only 30 302 patients were treated with an echinocandin in monotherapy, the criteria for 303 treatment inclusion were not specified, separate analyses for empirical and 304 targeted therapy were not performed, some variables that potentially influenced 305 outcome were not considered (including the appropriateness of empirical 306 treatment or early catheter removal) and PS adjustment was not used.
307
Overall, the patients treated with echinocandins were more acutely ill in 308 the present study, which probably reflects the fact that many physicians echinocandins and fluconazole, although the numbers in this subgroup were too 343 low to draw any conclusion.
344
The present study has several strengths. First, it is one of the largest 345 series on candidemia comparing the impact of fluconazole and echinocandins. was not possible to avoid survivor bias in the TTC; and some cases were lost 354 due to lack of therapy data.
355
In conclusion, our results suggest that using fluconazole for the empirical 
